Published in J Neurosci Res on June 01, 2010
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol (2012) 1.10
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One (2013) 1.03
Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03
The Synaptic Function of α-Synuclein. J Parkinsons Dis (2015) 0.98
Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol Dis (2010) 0.88
Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol (2013) 0.87
Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synuclein. PLoS One (2013) 0.86
Parkinson's disease mouse models in translational research. Mamm Genome (2011) 0.85
Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol Neurodegener (2011) 0.83
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Reduced expression of α-synuclein in alcoholic brain: influence of SNCA-Rep1 genotype. Addict Biol (2012) 0.80
Cell Biology and Pathophysiology of α-Synuclein. Cold Spring Harb Perspect Med (2017) 0.79
In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism. J Neurophysiol (2013) 0.77
Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice. BMC Neurosci (2017) 0.76
MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Oncotarget (2016) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Short-term synaptic plasticity. Annu Rev Physiol (2002) 16.67
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 6.92
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci (1999) 3.43
Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci (2006) 3.37
Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron (1995) 3.37
Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron (2004) 3.16
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci (1990) 2.54
Comparison of IPSCs evoked by spiny and fast-spiking neurons in the neostriatum. J Neurosci (2004) 2.42
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol (2001) 1.91
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci (2004) 1.74
alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J (2004) 1.54
In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol (2007) 1.51
Animal models of Parkinson's disease progression. Acta Neuropathol (2008) 1.49
Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci (2008) 1.49
Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol (1998) 1.46
Fast synaptic transmission between striatal spiny projection neurons. Proc Natl Acad Sci U S A (2002) 1.45
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience (1981) 1.40
Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol (1998) 1.39
Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci (2008) 1.33
Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J (2004) 1.26
Electrical and chemical transmission between striatal GABAergic output neurones in rat brain slices. J Physiol (2004) 1.25
Alpha-synuclein and transgenic mouse models. Neurobiol Dis (2004) 1.25
Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx (2005) 1.22
Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci (1994) 1.22
Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol (2001) 1.21
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain (1993) 1.19
Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res (2005) 1.15
Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport (2008) 1.15
Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl (2006) 1.09
Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J (2003) 1.07
Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis (2007) 1.02
Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience (2009) 1.00
Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci Lett (1984) 0.93
Dye-coupling in the neostriatum of the rat: I. Modulation by dopamine-depleting lesions. Synapse (1989) 0.91
Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons. Neurosci Lett (1987) 0.91
Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience (2005) 0.89
Glutamate in cortical fibers. Adv Biochem Psychopharmacol (1981) 0.87
Mechanisms and models of alpha-synuclein-related neurodegeneration. Curr Neurol Neurosci Rep (2006) 0.82
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Genome-wide analysis of clustered Dorsal binding sites identifies putative target genes in the Drosophila embryo. Proc Natl Acad Sci U S A (2001) 6.39
The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia (2010) 6.23
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature (2006) 4.54
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
Shadow enhancers as a source of evolutionary novelty. Science (2008) 3.71
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron (2004) 3.16
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 2.75
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem (2010) 2.67
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A (2004) 2.55
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Paused Pol II coordinates tissue morphogenesis in the Drosophila embryo. Cell (2013) 2.42
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol (2004) 2.37
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol (2010) 2.29
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Promoter elements associated with RNA Pol II stalling in the Drosophila embryo. Proc Natl Acad Sci U S A (2008) 2.25
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med (2012) 2.07
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Properties of developmental gene regulatory networks. Proc Natl Acad Sci U S A (2008) 2.05
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron (2003) 2.02
Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00
Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia (2009) 1.99
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84
Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol (2010) 1.81
Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron (2008) 1.81
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci (2010) 1.78
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature (2012) 1.75
A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc Natl Acad Sci U S A (2009) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
How the Dorsal gradient works: insights from postgenome technologies. Proc Natl Acad Sci U S A (2008) 1.70
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci (2006) 1.69
Comprehensive identification of Drosophila dorsal-ventral patterning genes using a whole-genome tiling array. Proc Natl Acad Sci U S A (2006) 1.66
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A (2008) 1.64
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci (2005) 1.63
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63